9 completed, 4 terminated, 1 unknown, 1 withdrawn. 7 Phase 2, 4 Phase 1, 2 Phase 3, 2 Phase 4, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Terminated 3, Withdrawn 1 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 2 | Completed 2 |
| Phase 4 | 2 | Completed 1, Unknown 1 |
| Early Phase 1 | 1 | Terminated 1 |
Follow Pioglitazone hydrochloride: new trials by email Literature Review of Pioglitazone hydrochloride trials Research Report on Pioglitazone hydrochloride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Role of Pioglitazone in Vascular Transcriptional Remodeling Pioglitazone 45 mg - Myocardial Reperfusion Injury | Phase 4 | Unknown | University of Campinas, Brazil | 20 | 2023-06-15 | 2024-01-12 |
| Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s Midazolam hydrochloride, Metoprolol tartrate, Pioglitazone hydrochloride - Healthy | Phase 1 | Completed | Corcept Therapeutics | 27 | 2018-03-06 | 2018-05-17 |
| Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia Pioglitazone, Tyrosine Kinase Inhibitor (TKI) - Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 2 | Terminated | Emory University | 9 | 2016-05-01 | 2019-01-09 |
| A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS DS-1971a, midazolam hydrochloride, Omeprazole - Healthy | Phase 1 | Completed | Daiichi Sankyo | 18 | 2015-05-01 | 2015-11-05 |
| Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock Pioglitazone hydrochloride - Severe Sepsis, Septic Shock | Phase 1 / Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 12 | 2011-10-01 | 2020-09-02 |
| Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-small Cell Lung Cancer Laboratory Biomarker Analysis, Pioglitazone Hydrochloride, Quality-of-Life Assessment - Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 6 | 2011-04-01 | 2017-12-05 |
| Pioglitazone in Early Parkinson's Disease Pioglitazone, placebo - Parkinson's Disease | Phase 2 | Completed | University of Rochester | 210 | 2011-03-01 | 2015-10-14 |
| Pioglitazone for Oral Premalignant Lesions Pioglitazone hydrochloride, placebo, laboratory biomarker analysis - Oral Leukoplakia | Phase 2 | Terminated | National Cancer Institute (NCI) | 52 | 2010-02-01 | 2016-04-06 |
| A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride When Given Together to Healthy Subjects ASP1941, pioglitazone hydrochloride - Healthy, Pharmacokinetics of ASP1941 | Phase 1 | Completed | Astellas Pharma Inc | 64 | 2009-11-01 | 2010-04-16 |
| Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine pioglitazone hydrochloride, laboratory biomarker analysis, questionnaire administration - Pancreatic Cancer | Early Phase 1 | Terminated | University of Texas Southwestern Medical Center | 6 | 2009-03-02 | 2018-11-26 |
| Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects Pioglitazone hydrochloride, Metformin hydrochloride - Type 2 Diabetes Mellitus | Phase 4 | Completed | University of Dhaka | 77 | 2008-11-01 | 2014-02-28 |
| MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2) Sitagliptin phosphate, Pioglitazone hydrochloride, Matching placebo to sitagliptin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1615 | 2008-09-05 | 2017-05-12 |
| Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients dapagliflozin, Glimepiride, metformin hydrochloride - Type 2 Diabetes | Phase 3 | Completed | AstraZeneca | 597 | 2008-04-01 | 2013-10-14 |
| Pioglitazone Hydrochloride (Actos(Registered Trademark)) to Treat Asthma Pioglitazone Hydrochloride - Asthma, Airway Inflammation | Phase 2 | Withdrawn | National Heart, Lung, and Blood Institute (NHLBI) | 2008-01-04 | 2017-07-02 | |
| Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia pioglitazone hydrochloride - Head and Neck Cancer, Oral Leukoplakia | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2003-06-01 | 2022-02-11 |
Diabetes Mellitus, Type 2 (3) · Leukoplakia, Oral (2) · Asthma (1) · Carcinoma, Non-Small-Cell Lung (1) · Head and Neck Neoplasms (1) · Hypersensitivity (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Myocardial Reperfusion Injury (1) · Pancreatic Neoplasms (1) · Parkinson Disease (1) · Sepsis (1) · Shock, Septic (1)
National Cancer Institute (NCI) (3) · Astellas Pharma Inc (1) · AstraZeneca (1) · Children's Hospital Medical Center, Cincinnati (1) · Corcept Therapeutics (1) · Daiichi Sankyo (1) · Emory University (1) · Merck Sharp & Dohme LLC (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · University of Campinas, Brazil (1) · University of Dhaka (1) · University of Rochester (1) · University of Texas Southwestern Medical Center (1)
United States (10) · Bangladesh (1) · Brazil (1) · Canada (1) · Czechia (1) · Hungary (1) · Italy (1) · Philippines (1) · Poland (1) · South Korea (1) · Thailand (1) · Ukraine (1) · United Kingdom (1)
AK Azad Chowdhury, PhD (1) · Andrei Sposito, Professor (1) · Begum Rokeya, PhD (1) · Colin Palmer, PhD (1) · Frank Ondrey (1) · Jennifer M. Kaplan, M.D., M.S. (1) · Karl Kieburtz, MD MPH (1) · Kirsteen Donaldson, FFPM,DM,FRCP (1) · Krzysztof Strojek, Prof. Dr. (1) · Masuma Parvin, PhD (1) · Paul Limburg (1) · Powel H. Brown (1) · Tanya Simuni, MD (1) · William Blum, MD (1)
PMID 39584361, PMID 21672123, PMID 23529567, PMID 23909985, PMID 25227476, PMID 26116315, PMID 30255316, PMID 33368935, PMID 39532605
N01CN00042 (1), N01CN35000 (1), N01CN35153 (1), N01CN35159 (1), P30CA015083 (1), P30CA016672 (1), U01NS043128 (1)